Ian E. Krop, MD, PhD

Ian Krop, MD, PhD, discusses zanidatamab in combination with evorpacept in HER2-positive and HER2-low metastatic breast cancer.

Ian Krop, MD, PhD, discusses SHR-A1811, a third-generation antibody-drug conjugate for HER2-positive breast cancer.

Ian E. Krop, MD, PhD, discusses the use of fam-trastuzumab deruxtecan-nxki across age groups in the DESTINY Breast trials in patients with HER2-positive metastatic breast cancer.

Closing thoughts on the TALENT study concerning the use of neoadjuvant trastuzumab deruxtecan in patients with HER2-low, HR+ early-stage breast cancer.

Dr Geyer and Dr Krop discuss key data and the evolving standard of care for patients with HER2-low breast cancer.

Breast cancer experts exchange thoughts on the treatment of HER2+ breast cancer with CNS involvement, particularly the use of trastuzumab deruxtecan in this subset of patients.

Dr Krop leads a discussion of results from the DESTINY-Breast02 and DESTINY-Breast03 studies concerning the use of trastuzumab deruxtecan in patients with metastatic breast cancer.

Charles E. Geyer, MD and Ian E. Krop, MD, PhD touch on recent advances in the metastatic HR+ breast cancer setting and evaluate PROTAC estrogen receptor (ER) degraders compared with other ER modulators.

Conversation centered around the clinical implications of recently presented data from the randomized, multi-dose phase II SERENA-2 trial.

Dr Geyer and Dr Krop explore data from the OlympiA phase III trial of adjuvant olaparib in patients with variants in BRCA1/2.

Two breast cancer experts review updates from the SOFT and TAILORx trials and discuss racial disparities in breast cancer treatment and clinical trials.

Charles E. Geyer, MD and Ian E. Krop, MD, PhD provide an overview of the current breast cancer treatment landscape, with a focus on the management of patients with ER+/HER2- metastatic breast cancer.

Ian E. Krop, MD, PhD, discusses the need to evaluate de-escalated treatment strategies in HER2-positive breast cancer.

Ian E. Krop, MD, PhD, discusses progress made in 2021 in the management of HER2-positive breast cancer.

Ian E. Krop, MD, PhD, discusses the role of neratinib as extended adjuvant therapy in high-risk, hormone receptor–positive, HER2-positive breast cancer.

Ian E. Krop, MD, PhD, chief, Breast Oncology, Susan F. Smith Center for Women’s Cancers, clinical research director, Breast Oncology Center, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the impact of recent advances in breast cancer.

As the field evolves, it is likely that HER2-directed agents will be used to an increasing extent instead of conventional chemotherapy, further reducing toxicity.